Skip to main content

FDA Approvals

Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer

FDA Approvals, Leukemia, Oncology

Oral Onureg First Drug Approved for Adults with AML in Remission

Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions

Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma

FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tecartus First CAR T-Cell Therapy FDA Approved for Patients with Mantle-Cell Lymphoma

Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh

Page 15 of 53
Results 141 - 150 of 527